<DOC>
	<DOCNO>NCT00526799</DOCNO>
	<brief_summary>This multi-institutional phase I/II clinical trial test tolerability efficacy combination sorafenib topotecan patient recurrent ovarian cancer , platinum-resistant ( recurrence within 6 month complete platinum base therapy ) refractory ( progressive disease platinum base therapy ) .</brief_summary>
	<brief_title>Sorafenib + Topotecan Platinum-Resistant Recurrent Ovarian Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . - Topotecan : 4mg/m2 weekly , 3 week one week . - Sorafenib : Assigned cohort dose phase I ( 12 patient ) Maximum tolerate dose phase II ( 21 total patient ) Cycles consist 4 week ( 28 day ) disease evaluation every 8 week . Non-PD acceptable toxicity : Patients continue protocol therapy PD unacceptable toxicity : Patients discontinue protocol therapy ECOG performance status 0-1 Life expectancy : Three ( 3 ) month Hematopoietic : - White blood cell count ( WBC ) &gt; 3 K/mm3 - Hemoglobin ( Hgb ) &gt; 9 g/dL - Platelets &gt; 100 K/mm3 - Absolute neutrophil count ( ANC ) &gt; 1.5 K/mm3 - INR &lt; 1.5 PTT within normal limit . NOTE : Patients receive anti-coagulation treatment agent warfarin heparin may allow participate . - No evidence history bleed diathesis coagulopathy . Hepatic : - Bilirubin &lt; 1.5 x ULN - Aspartate aminotransferase ( AST , SGOT ) &lt; 2.5 x ULN - Alanine aminotransferase ( ALT , SGPT ) &lt; 2.5 x ULN - Alkaline phosphate &lt; 2.5 x ULN Renal : - Creatinine &lt; 1.5 x ULN Cardiovascular : - No history myocardial infarction angina pectoris angina equivalent within 6 month prior registration protocol therapy ( patient may anti-anginal anti-arrhythmic medication ) , uncontrolled hypertension congestive heart failure &gt; class II NYHA Pulmonary : - No thrombolic embolic event cerebrovascular accident , include transient ischemic attack within past 6 month . - No pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within 28 day prior registration protocol therapy . - No non-pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 3 within 28 day prior registration protocol therapy .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Have histologicallyconfirmed epithelial ovarian cancer , primary peritoneal carcinomatosis fallopian tube cancer . Enrollment patient clear cell histology encourage . Have measurable disease accord RECIST detectable disease 1 ) CA125 least twice ULN within 14 day prior registration protocol therapy ; 2 ) Ascites and/or pleural effusion attribute tumor ; 3 ) solid and/or cystic abnormality radiographic image meet RECIST definition target lesion . Have fail least one prior platinum base chemotherapeutic regimen . No 3 prior treatment regimens epithelial ovarian cancer . Prior radiation therapy allow &lt; 25 % bone marrow . Be least 4 week since last anticancer treatment , radiation surgery time registration protocol therapy . No active cancer addition epithelial ovarian cancer within last 5 year , exception : superficial skin cancer ( basal cell squamous cell skin carcinoma ; carcinoma situ cervix ; Stage I endometrial cancer le 50 % invasion myometrium , adequately treated Stage I II cancer complete remission . Age &gt; 18 year time consent Written inform consent HIPAA authorization release personal health information . Females childbearing potential must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent sign 90 day treatment discontinuation Females childbearing potential must negative pregnancy test within 7 day prior register protocol therapy . No know suspect allergy sorafenib agent give course trial . No prior treatment antiangiogenesis therapy . No active CNS metastasis . No treatment investigational agent within 30 day prior register protocol therapy . No concurrent combination antiretroviral therapy treatment immunodeficiency . No clinically significant infection require antibiotic treatment . No evidence bowel obstruction , malabsorption , contraindication oral medication . No serious nonhealing wound , ulcer , bone fracture . No major surgery , open biopsy significant traumatic injury within 28 day registration protocol therapy . No use St. John 's Wort rifampin ( rifampicin ) protocol therapy . No condition impair patient 's ability swallow whole pill .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>